US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey.
about
Psoriasis and Atopic Dermatitis.Co-morbidity in psoriasis: mechanisms and implications for treatment.Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor: A novel treatment option for nurse practitioners treating patients with psoriatic diseaseMisalignment between physicians and patient satisfaction with psoriatic arthritis disease control.Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications.Patients' perspectives in the management of psoriasis: the Italian results of the Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey.Dermatologist and Patient Preferences in Choosing Treatments for Moderate to Severe Psoriasis.Interleukin-17 alters the biology of many cell types involved in the genesis of psoriasis, systemic inflammation and associated comorbidities.Consensus on the management of patients with psoriatic arthritis in a dermatology setting.Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future.Combining biologic and phototherapy treatments for psoriasis: safety, efficacy, and patient acceptability.Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study.Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient-perceived treatment effectiveness, medication use, and healthcare resource utilizationGuselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study
P2860
Q30238648-D53720D0-0951-4D8A-BF56-BBECAD202333Q30248952-1DB29CAE-C12B-4548-ADCF-66F183BCF3D6Q37505449-6B7DBE5C-C8BE-44CD-92D6-C9FF258D6385Q38941723-77973696-606A-4BCE-8387-F263C4C8464CQ39004668-E2388B12-2221-4214-AB02-370053A1416BQ39165009-710603E6-AD8D-47ED-A1E2-41B0D6105EA6Q47116889-CA5CC42F-F2E6-46C8-A041-983292195A87Q47704613-C744924B-1BDB-432E-873C-4DD7C6D90566Q50002313-E59113BB-F282-4CF0-879F-A02608C4DDF1Q52651099-35A7CDD4-AE2C-4935-9E86-910F839F9A3FQ55119166-08D26337-5DD8-4643-8C07-94D758F9AED7Q55195946-B3C0D200-985B-48BE-9304-83BF105BFB8CQ55515872-F3D63A2F-5D2A-4FB0-B20E-097357F86AA7Q57705930-57857D4B-E95C-4DFD-A74B-1FE901521606
P2860
US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
US Perspectives in the Managem ...... iatic Arthritis (MAPP) Survey.
@ast
US Perspectives in the Managem ...... iatic Arthritis (MAPP) Survey.
@en
type
label
US Perspectives in the Managem ...... iatic Arthritis (MAPP) Survey.
@ast
US Perspectives in the Managem ...... iatic Arthritis (MAPP) Survey.
@en
prefLabel
US Perspectives in the Managem ...... iatic Arthritis (MAPP) Survey.
@ast
US Perspectives in the Managem ...... iatic Arthritis (MAPP) Survey.
@en
P2093
P2860
P1476
US Perspectives in the Managem ...... iatic Arthritis (MAPP) Survey.
@en
P2093
Abby S Van Voorhees
April W Armstrong
Arthur Kavanaugh
Mark G Lebwohl
P2860
P2888
P356
10.1007/S40257-015-0169-X
P577
2015-12-30T00:00:00Z